Literature DB >> 10685650

Interleukin-2 and the development of immunotherapy for the treatment of patients with cancer.

S A Rosenberg1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2000        PMID： 10685650

Source DB:  PubMed          Journal:  Cancer J Sci Am        ISSN： 1081-4442


× No keyword cloud information.
  24 in total

1.  The VE-PTP Inhibitor AKB-9778 Improves Antitumor Activity and Diminishes the Toxicity of Interleukin 2 (IL-2) Administration.

Authors:  Guanqiao Li; Ulka Sachdev; Kevin Peters; Xiaoyan Liang; Michael T Lotze
Journal:  J Immunother       Date:  2019-09       Impact factor: 4.456

Review 2.  Checkpoint blockade in cancer immunotherapy.

Authors:  Alan J Korman; Karl S Peggs; James P Allison
Journal:  Adv Immunol       Date:  2006       Impact factor: 3.543

Review 3.  Enhancing cancer immunotherapy by intracellular delivery of cell-penetrating peptides and stimulation of pattern-recognition receptor signaling.

Authors:  Helen Y Wang; Rong-Fu Wang
Journal:  Adv Immunol       Date:  2012       Impact factor: 3.543

Review 4.  The role of natural killer cells in tumor control--effectors and regulators of adaptive immunity.

Authors:  Morgan E Wallace; Mark J Smyth
Journal:  Springer Semin Immunopathol       Date:  2005-02-24

5.  Potentiation of antitumor effect of NKT cell ligand, alpha-galactosylceramide by combination with IL-12 on lung metastasis of malignant melanoma cells.

Authors:  M Nakui; A Ohta; M Sekimoto; M Sato; K Iwakabe; T Yahata; H Kitamura; T Koda; T Kawano; H Makuuchi; M Taniguchi; T Nishimura
Journal:  Clin Exp Metastasis       Date:  2000       Impact factor: 5.150

Review 6.  Natural killer cells in inflammatory heart disease.

Authors:  SuFey Ong; Noel R Rose; Daniela Čiháková
Journal:  Clin Immunol       Date:  2016-11-25       Impact factor: 3.969

7.  A phase I study of nonmyeloablative chemotherapy and adoptive transfer of autologous tumor antigen-specific T lymphocytes in patients with metastatic melanoma.

Authors:  Mark E Dudley; John R Wunderlich; James C Yang; Patrick Hwu; Douglas J Schwartzentruber; Suzanne L Topalian; Richard M Sherry; Francesco M Marincola; Susan F Leitman; Claudia A Seipp; Linda Rogers-Freezer; Kathleen E Morton; Azam Nahvi; Sharon A Mavroukakis; Donald E White; Steven A Rosenberg
Journal:  J Immunother       Date:  2002 May-Jun       Impact factor: 4.456

8.  Novel SHP-1 inhibitors tyrosine phosphatase inhibitor-1 and analogs with preclinical anti-tumor activities as tolerated oral agents.

Authors:  Suman Kundu; Keke Fan; Mingli Cao; Daniel J Lindner; Zhizhaung Joe Zhao; Ernest Borden; Taolin Yi
Journal:  J Immunol       Date:  2010-04-26       Impact factor: 5.422

Review 9.  NK cell-based immunotherapy for malignant diseases.

Authors:  Min Cheng; Yongyan Chen; Weihua Xiao; Rui Sun; Zhigang Tian
Journal:  Cell Mol Immunol       Date:  2013-04-22       Impact factor: 11.530

10.  IL-15 acts as a potent inducer of CD4(+)CD25(hi) cells expressing FOXP3.

Authors:  Hiromi Imamichi; Irini Sereti; H Clifford Lane
Journal:  Eur J Immunol       Date:  2008-06       Impact factor: 5.532
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.